Organization Overview
Alternative names
activated marrow infiltrating lymphocytes (1 trial)
aldesleukin (Proleukin) (2 trials)
allogeneic hematopoietic stem cells (Hemacord) (1 trial)
allogeneic natural killer cells (3 trials)
allopurinol (zyloprim) (1 trial)
alpha-1 antitrypsin (Prolastin) (1 trial)
autologous ex-vivo expanded effector cells (1 trial)
cd3,cd19 depleted hematopoietic stem cells (1 trial)
dc/aml fusion vaccine (1 trial)
donor-derived ebv-specific cytotoxic t-cells transduced with the retroviral vector sfgalpha-cd19-cd3zeta (1 trial)
Filgrastim (neupogen) (1 trial)
allogeneic stem cells (1 trial)
bortezomib (velcade) (1 trial)
cyclophosphamide (cytoxan) (2 trials)
dimethyl fumarate (tecfidera) (1 trial)
durvalumab (imfinzi) (1 trial)
everolimus (zortress) (1 trial)
Acute Disease (Phase 1)
Blast Crisis (Phase 1)
Graft vs Host Disease (Phase 2)
Hodgkin Disease (Phase 2)
Leukemia (Phase 3)
Leukemia, Biphenotypic, Acute (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Mast-Cell (Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myelomonocytic, Acute (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Myelomonocytic, Juvenile (Phase 3)
Leukemia, Prolymphocytic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 1)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Paraproteinemias (Phase 1)
Polycythemia (Phase 1)
Polycythemia Vera (Phase 1)
Preleukemia (Phase 3)
Primary Myelofibrosis (Phase 1)
Syndrome (Phase 3)
Thrombocythemia, Essential (Phase 1)
Thrombocytosis (Phase 1)
Vitamin D Deficiency (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)